Relative value of the NSAIDs, including COX-2 inhibitors and meloxicam

Journal of Managed Care Pharmacy

Volumn 12, Issue 3, 2006, Pages 265-268

  Curtiss, Frederic R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; ROFECOXIB; VALDECOXIB; PROSTAGLANDIN SYNTHASE INHIBITOR; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

CLINICAL TRIAL; DIARRHEA; DRUG COST; DRUG MECHANISM; DRUG WITHDRAWAL; EDITORIAL; GASTROINTESTINAL HEMORRHAGE; HEMATEMESIS; HUMAN; INFLAMMATION; META ANALYSIS; NAUSEA; PEPTIC ULCER; RISK ASSESSMENT; RISK REDUCTION; SKIN MANIFESTATION; SYSTEMATIC REVIEW; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; ECONOMICS; NOTE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; GASTROINTESTINAL HEMORRHAGE; HUMANS; RISK ASSESSMENT; THIAZINES; THIAZOLES;

EID: 33747427382     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2006.12.3.265     Document Type: Editorial

References (27)

1. Klein T. Nusing RM, Pfeilschifter J, Ullrich V. Selective inhibitor of cyclooxygenase 2. Biochem Pharmaco. 1994;48(8):1605-10.
2. PubMed search on "Cox-2." Available at: http://www.ncbi.nlm. nih.gov/entrez/ query.fcgi?CMD=search&DB=pubmed. Accessed March 22, 2006.
3. Ortiz E. Market withdrawal of Vioxx: is it time to rethink the use of COX-2 inhibitors? J Manag Care Pharm. 2004;10(6):551-54.
4. Stockl K, Cyprien L, Chang EY. Gastrointestinal bleeding rates among managed care patients newly started on COX-2 inhibitors or nonselective NSAIDs. J Manag Care Pharm. 2005;11(7):550-58.
5. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;331:1310-16.
6. Abraham NS, El-Serage HB, Johnson ML, et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology. 2005;129(4):1171-78. Available at: http://download.journals.elsevierhealth.com/pdfs/journals/0016-5085/ PIIS0016508505015787.pdf. Accessed March 22, 2006.
7. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med. 2005;165:978-84.
8. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002;347:2104-10.
9. Wom Tesoriero H, Hensley S. Prices increase on popular drugs. Wall Street Journal. January 25, 2005:D1.
10. U.S. Food and Drug Administration. Medication Guide, Mobic (meloxicam) Wall Street Journal. January 25, 2005:D1. Available at: http://www.fda.gov/ medwatch/safety/2005/aug_PI/Mobic_PI.pdf. Accessed March 22, 2006.
11. Pharmacy claims search performed March 22, 2006, of the data warehouse of a national pharmacy benefits manager representing approximately 500,000 beneficiaries of small employer drug benefit plans for pharmacy claims with dates of service from January 1, 2006, through March 15, 2006. Cost is the allowed charge (drug cost + dispense fee) prior to subtraction of beneficiary copayment or manufacturer rebates.
12. U.S. Food and Drug Administration. FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the product. P04-95, September 30, 2004. Available at: http://www.fda.gov/bbs/topics/news/2004/ NEW01122.html. Accessed August 1, 2005.
13. FDA Alert for Healthcare Professionals - valdecoxib (marketed as Bextra) - 04/07/05. Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/ valdecoxibHCP.pdf. Accessed July 27, 2005.
14. Mathews AW, Hensley S. FDA stiffens painkiller warnings, pushing Pfizer to suspend Bextra. Wall Street Journal. April 8, 2005:A1, A4.
15. Non-steroidal anti-inflammatory agents, NSAIDs adverse reactions (%). Facts and Comparisons, CliniSphere Version ISBN 1-57439-036-8, May 2005, St. Louis, MO. Wolters Kluwer Health, Inc.
16. Curtiss FR. COX-2 inhibitors: little or no GI protection, increased risk of cardiovascular events, high cost, and other class-less effects. J Manag Care Pharm. 2005;11(7):590-93.
17. Tesoriero HW, Tomsho R, Winslow R. Vioxx plaintiffs seek mistrial after allegation on Merck study. Wall Street Journal. December 10-11, 2005:A1, A9.
18. Harris G, Carroll J. Panel approves Merck's claims for arthritis drug. Wall Street Journal. February 9, 2001:B10.
19. Prescribing information from the product label for meloxicam (Mobic) reported in Drug Facts and Comparisons (Clinisphere version ISBN 1-57439-036-8). St. Louis, MO: Wolters, Kluwer Health, Inc. February 2006. Accessed March 17, 2006.
20. Yocum D, Fleischmann R, Dalgin P, Caldwell J, Hall D, Roszko P, for the Meloxicam Osteoarthritis Investigators. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. Arch Intern Med. 2000;160:2947-54.
21. Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-sterodial anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis. 2004;63:759-66.
22. Singh G. Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med. 2004;117(2)100-06.
23. Martin RM, Biswas P, Mann RD. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study. Brit J Clin Pharmacol. 2000;50(1):35-42.
24. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Application no. 20-938. Final printed labeling - Mobic. Available at: http://www.fda.gov/cder/foi/nda/2000/20-938_Mobic_prntlbl.pdf. Accessed March 26, 2006.
25. MacDonald TM, Morant SV, Goldstein JL, Burke TA, Pettitt D. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut. 2003;52:165-70.
26. Garner SE, Fidan DD, Frankish RR, et al. Celecoxib for rheumatoid arthritis. Cochrane review abstract and plan language summary. Full text in The Cochrane Library. Summary available at: http://www.cochrane.org/ reviews/en/ ab003831.html. Accessed March 22, 2006.
27. The Emperor's New Clothes by Hans Christian Andersen (1805-1875), adapted by Stephen Corrin in Stories for Seven-Year-Olds. London 1964. Available at: http://www.mindfully.org/Reform/Emperors-New-Clothes.htm. Accessed March 22, 2006.